» 
OP Team steps up
Copy URL
https://www.pharmnovo.com/post/op-team-steps-up

OP Team steps up

September 5, 2022

PharmNovo AB is pleased to announce that the company has strengthened the team when entering the clinical phase with PN6047. Tommy Nilsson takes on the role of CFO, and Jarkko Kalliomäki will support clinical management and work with the design and development of clinical studies.

In August, PharmNovo started clinical studies of its drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain, after raising SEK 73 million in an issue led by Sciety earlier this summer.

Tommy Nilsson has a background as CFO at subsidiaries of Electrolux and Ericsson. He has worked as interim CFO for businesses in several industries for the past years. At PharmNovo, he will lead financial management and reporting, build up the company's routines and processes, and prepare the company for future follow-on financing.

Jarkko Kalliomäki is a specialist in pain and pain relief and holds an MD in Physiology. He has over ten years of experience as a Senior Clinical Research Physician at AstraZeneca R&D in Södertälje in several pain-related projects. He works as a consultant in rehabilitation medicine and pain relief at, among others, Sophiahemmet, PBM, and St. Göran's Hospital. Jarkko will support clinical management and work with the design and development of the clinical studies in close collaboration with Olof Breuer, CMO at PharmNovo.

Press release

LinkedIn

Petra Larson
Author:
Petra Larson

Latest news

View all
December 22, 2022

PharmNovo at Biostock

CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.

Read more
December 22, 2022

Seasons Greetings 2022

The PharmNovo team would like to wish you a Merry Christmas and a Happy New Year!

Read more
October 11, 2022

Strengthening the team

PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical Trial Manager

Read more
September 20, 2022

Good press in SvD

Read the story about PharmNovo and our drug candidate PN6047 for neurophatic pain and its ongoing phase I studies in Svenska Dagbladet.

Read more

By using this website, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.

Awesome 👌
← Back
No items found.
September 5, 2022

OP Team steps up

PharmNovo AB is pleased to announce that the company has strengthened the team when entering the clinical phase with PN6047. Tommy Nilsson takes on the role of CFO, and Jarkko Kalliomäki will support clinical management and work with the design and development of clinical studies.

In August, PharmNovo started clinical studies of its drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain, after raising SEK 73 million in an issue led by Sciety earlier this summer.

Tommy Nilsson has a background as CFO at subsidiaries of Electrolux and Ericsson. He has worked as interim CFO for businesses in several industries for the past years. At PharmNovo, he will lead financial management and reporting, build up the company's routines and processes, and prepare the company for future follow-on financing.

Jarkko Kalliomäki is a specialist in pain and pain relief and holds an MD in Physiology. He has over ten years of experience as a Senior Clinical Research Physician at AstraZeneca R&D in Södertälje in several pain-related projects. He works as a consultant in rehabilitation medicine and pain relief at, among others, Sophiahemmet, PBM, and St. Göran's Hospital. Jarkko will support clinical management and work with the design and development of the clinical studies in close collaboration with Olof Breuer, CMO at PharmNovo.

Press release

LinkedIn

September 5, 2022

OP Team steps up

PharmNovo AB is pleased to announce that the company has strengthened the team when entering the clinical phase with PN6047. Tommy Nilsson takes on the role of CFO, and Jarkko Kalliomäki will support clinical management and work with the design and development of clinical studies.

In August, PharmNovo started clinical studies of its drug candidate PN6047 for the treatment of neuropathic pain, so-called nerve pain, after raising SEK 73 million in an issue led by Sciety earlier this summer.

Tommy Nilsson has a background as CFO at subsidiaries of Electrolux and Ericsson. He has worked as interim CFO for businesses in several industries for the past years. At PharmNovo, he will lead financial management and reporting, build up the company's routines and processes, and prepare the company for future follow-on financing.

Jarkko Kalliomäki is a specialist in pain and pain relief and holds an MD in Physiology. He has over ten years of experience as a Senior Clinical Research Physician at AstraZeneca R&D in Södertälje in several pain-related projects. He works as a consultant in rehabilitation medicine and pain relief at, among others, Sophiahemmet, PBM, and St. Göran's Hospital. Jarkko will support clinical management and work with the design and development of the clinical studies in close collaboration with Olof Breuer, CMO at PharmNovo.

Press release

LinkedIn

Author:

Petra Larson

Author:

Petra Larson

PharmNovo at Biostock

CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.

Read more →

Seasons Greetings 2022

The PharmNovo team would like to wish you a Merry Christmas and a Happy New Year!

Read more →

Strengthening the team

PharmNovo has strengthened the team with a new experienced Project Manager and a Clinical Trial Manager

Read more →

Good press in SvD

Read the story about PharmNovo and our drug candidate PN6047 for neurophatic pain and its ongoing phase I studies in Svenska Dagbladet.

Read more →
Latest
breaking
news

Find us

PharmNovo AB
Medicon Village AB
Scheeletorget 1
SE-223 81 Lund, Sweden

Map